Evidence Hub

Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension

Nour S, Dai G, Carbognani D, Feng M, Yang D, Lila N, Chachques JC, Wu G

Pediatric cardiology, 2012

6 participants

Abstract

OBJECTIVE: Pulmonary arterial hypertension (PAH) is a dysfunctional endothelium disease with increased pulmonary vascular resistance (PVR) and poor prognosis. Current therapies are still insufficient. Here we propose a new pulsatile device as a more effective tool for PAH management compared with traditional treatments.

MATERIALS AND METHODS: Twelve piglets (10.3 ± 3.8 kg) were given either intrapulmonary pulsatile [P (n = 6)] or nonpulsatile [NP (n = 6)] tadalafil treatment. After median sternotomy and heparin injection (250 IU/kg), both groups underwent aorto-pulmonary surgical shunt for 1 h. During a second 1 h period in group P, a catheter prototype, driven by a small ventilator, was introduced into the pulmonary trunk and pulsated intermittently at 110 bpm irrespective of heart rate (90.6 ± 10.74 bpm). In group NP, tadalafil was given orally (1 mg/kg).

RESULTS: Hemodynamics and cardiac output (CO) were significantly (p 0.05) greater in group P (0.81 ± 0.78) versus (0.62 ± 0.35) group NP.

CONCLUSION: Induced with an appropriate device, intrapulmonary shear stress-mediated endothelial function enhancement provides a more effective nearly physiological therapy for PAH.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free